Royalty Pharma plcRPRXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +5.29% | -0.41% | +0.05% | +7.71% | +7.90% |
| Gross Profit Growth | +117.88% | -0.41% | +0.05% | +7.71% | +7.90% |
| EBITDA Growth | +471.02% | -47.69% | +1148.01% | -34.55% | -39.85% |
| Operating Income Growth | +385.38% | -41.02% | +0.00% | -22.19% | -41.89% |
| Net Income Growth | +654.34% | -57.88% | +4888.47% | -70.42% | -47.02% |
| EPS Growth | +655.78% | -57.74% | +5063.21% | -68.52% | -45.09% |
| EPS Diluted Growth | +658.56% | -57.76% | +5042.45% | -68.63% | -45.18% |
| Weighted Average Shares Growth | -0.54% | -0.13% | -5.13% | -4.15% | -3.17% |
| Weighted Average Shares Diluted Growth | -1.35% | +31.89% | -3.26% | -5.85% | -5.63% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +22.68% | -3.90% | -10.32% | -35.13% | -9.09% |
| Free Cash Flow Growth | +22.68% | -3.90% | -10.32% | -35.13% | -8.94% |
| Receivables Growth | -34.32% | +20.31% | +7.01% | +17.65% | +3470.03% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +13.79% | +11.24% | +9.16% | +3.77% | +7.23% |
| Book Value per Share Growth | +12.51% | +6.58% | +8.48% | +2.27% | -3.57% |
| Debt Growth | +24.08% | +24.08% | +24.08% | +5.27% | +17.86% |
| R&D Expense Growth | -99.01% | +0.00% | +10000.00% | +60000.00% | +10000.00% |
| SG&A Expenses Growth | -0.90% | +14.20% | +92.02% | +228.60% | +109.33% |